Modulators of the integrated stress pathway

A compound of Formula (I):

• or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:
• D is a bridged monocyclic cycloalkyl, bridged monocyclic heterocyclyl, or cubanyl, wherein each bridged monocyclic cycloalkyl, bridged monocyclic heterocyclyl, or cubanyl is optionally substituted with 1-4 RX;
• L1 and L2 are each independently C1-C6 alkylene or 2-7-membered heteroalkylene, wherein each C1-C6 alkylene or 2-7-membered heteroalkylene is optionally substituted with 1-5 RX;
• R1 and R2 are each independently hydrogen, C1-C6 alkyl, C1-C6 alkoxy-C1-C6 alkyl, hydroxy-C1-C6 alkyl, silyloxy-C1-C6 alkyl;
• A and W are each independently phenyl or 5-6 membered heteroaryl, wherein each phenyl or 5-6-membered heteroaryl is optionally substituted with 1-5 RY;
• each RX is independently selected from the group consisting of C1-C6 alkyl, hydroxy-C1-C6 alkyl, halo-C1-C6 alkyl, amino-C1-C6 alkyl, cyano-C1-C6 alkyl, oxo, halo, cyano, —ORA, —NRBRC, —NRBC(O)RD, —C(O)NRBRC, —C(O)RD, —C(O)OH,—C(O)ORD, —SRE, —S(O)RD, and —S(O)2RD;
• each RY is independently selected from the group consisting of hydrogen, C1-C6 alkyl, hydroxy-C1-C6 alkyl, C1-C6 alkoxy-C1-C6 alkyl, halo-C1-C6 alkyl, halo-C1-C6 alkoxy, amino-C1-C6 alkyl, cyano-C1-C6 alkyl, oxo, halo, cyano, —ORA, —NRBRC, —NRBC(O)RD, —C(O)NRBRC, —C(O)RD, —C(O)OH, —C(O)ORD, —S(RF)m, —S(O)RD, —S(O)2RD, and G1;
• or
• 2 RY groups on adjacent atoms, together with the atoms to which they are attached form a 3-7-membered fused cycloalkyl, 3-7 membered heterocyclyl, aryl, or 5-6 membered heteroaryl, optionally substituted with 1-5 RX;
• each G1 is independently C3-C6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl, wherein each C3-C6 cycloalkyl, 4-7-membered heterocyclyl, aryl, or 5-6-membered heteroaryl is optionally substituted with 1-3 RZ;
• each RZ is independently selected from the group consisting of C1-C6 alkyl, hydroxy-C1-C6 alkyl, halo-C1-C6 alkyl, halo, cyano, —ORA, —NRBRC, —NRBC(O)RD, —C(O)NRBRC, —C(O)RD, —C(O)OH, —C(O)ORD, and —S(O)2RD;
• RA is, at each occurrence, independently hydrogen, C1-C6 alkyl, halo-C1-C6 alkyl, —C(O)NRBRC, —C(O)RD, —C(O)OH, or —C(O)ORD;
• each of RB and RC is independently hydrogen or C1-C6 alkyl;
• or RB and RC together with the atom to which they are attached form a 3-7-membered heterocyclyl optionally substituted with 1-3 RZ;
• each RD is independently C1-C6 alkyl, halo-C1-C6 alkyl, or —NRB1RC1;
• each RE is independently hydrogen, C1-C6 alkyl, or halo-C1-C6 alkyl;
• each RF is independently hydrogen, C1-C6 alkyl, halo, or halo-C1-C6 alkyl;
• each of RB1 and RC1 is independently hydrogen or C1-C6 alkyl;
• and
• m is 1, 3, or 5.